These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

145 related items for PubMed ID: 2530543

  • 41.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 42.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 43.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 44.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 45.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 46. Cefixime. A review of its antibacterial activity. Pharmacokinetic properties and therapeutic potential.
    Brogden RN, Campoli-Richards DM.
    Drugs; 1989 Oct; 38(4):524-50. PubMed ID: 2684593
    [Abstract] [Full Text] [Related]

  • 47.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 48.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 49.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 50.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 51. [Cefixime therapy in patients with proven gonorrhea].
    Backhaus A, Tinzl J.
    Infection; 1990 Oct; 18 Suppl 3():S145-6. PubMed ID: 2079375
    [Abstract] [Full Text] [Related]

  • 52. [Cefixime. Microbiologic, kinetic and clinical profile].
    Di Nola F, Arione R, Bramato C.
    Minerva Med; 1991 Oct; 82(10):633-56. PubMed ID: 1745375
    [Abstract] [Full Text] [Related]

  • 53. Comparative study of efficacy and safety of ciprofloxacin and cefixime in the treatment of acute exacerbations of chronic bronchitis after first-line treatment failure. French Study Group.
    Nouvet G, Benmessaoud K.
    Drugs; 1995 Oct; 49 Suppl 2():423-5. PubMed ID: 8549386
    [No Abstract] [Full Text] [Related]

  • 54.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 55.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 56. Clinical role of Cefixime in community-acquired infections.
    Dreshaj Sh, Doda-Ejupi T, Tolaj IQ, Mustafa A, Kabashi S, Shala N, Geca Nj, Aliu A, Daka A, Basha N.
    Prilozi; 2011 Oct; 32(2):143-55. PubMed ID: 22286619
    [Abstract] [Full Text] [Related]

  • 57. Comparative evaluation of cefpodoxime versus cefixime in children with lower respiratory tract infections.
    Sengupta J, Mondal AK, Jain P, Garg RD, Mathur NC, Moharana AK.
    Indian J Pediatr; 2004 Jun; 71(6):517-21. PubMed ID: 15226561
    [Abstract] [Full Text] [Related]

  • 58. Efficacy and safety of oral cefixime therapy in common infectious diseases in children.
    Lee PI, Lee CY, Chen JM, Huang LM, Hwang KC, Lee MJ.
    Zhonghua Min Guo Xiao Er Ke Yi Xue Hui Za Zhi; 1991 Jun; 32(3):145-50. PubMed ID: 1776438
    [Abstract] [Full Text] [Related]

  • 59. Noncomparative, open label, multicenter trial of cefixime for treatment of bacterial pharyngitis, cystitis and pneumonia in pediatric patients.
    Risser WL, Barone JS, Clark PA, Simpkins DL.
    Pediatr Infect Dis J; 1987 Oct; 6(10):1002-6. PubMed ID: 3320921
    [Abstract] [Full Text] [Related]

  • 60. [Infections in childhood; from respiratory infections to tropical medicine].
    Fortschr Med Suppl; 1993 Oct; 144():1-8. PubMed ID: 9260316
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.